CL2A-SN-38

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CL2A-SN-38 是一种药物-接头缀合物，由有效的 DNA 拓扑异构酶 I 抑制剂 SN-38 和接头 CL2A 组成，用于制备抗体药物缀合物 (ADC)。

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond.

——

——

——

Antibody Drug Conjugates (ADC)

Drug-Linker Conjugates

——

——

——

1279680-68-0

1480.61

C??H??N??O??

>98% (HPLC)

DMSO : 100 mg/mL (67.54 mM; Need ultrasonic)

O=C(O[C@](C1=C(CO2)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C1)=O)(CC)C2=O)OCC6=CC=C(NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7N=NC(CNC(C8CCC(CN9C(C=CC9=O)=O)CC8)=O)=C7)=O)=O)=O)C=C6

——

(-20℃)

With Ice Pack

≥ 2 years